BACKGROUND: Omega-3 (n-3) fatty acids have shown benefit in cognitively impaired subjects, but the effect on cognitively healthy older subjects is unclear. OBJECTIVES: Our aim was to determine if long-term, high-dose ω-3 ethyl esters, EPA (20:5n-3) and DHA (22:6n-3), prevent deterioration of cognitive function in cognitively healthy older adults. METHODS: A total of 285 subjects with stable coronary artery disease (CAD) on statin treatment were randomly assigned to 3.36 g EPA and DHA or none (control) for 30 mo. Cognitive function was assessed in all 285 subjects at baseline and in 268 and 250 subjects who returned at 12- and 30-mo follow-up, respectively, with neuropsychological testing as a prespecified secondary outcome. A completer's analysis, along with a sensitivity analysis carrying forward the last observation, was performed. RESULTS: Over the 30-mo period, subjects randomly assigned to EPA and DHA had significantly better scores than control for verbal fluency, language, and memory (mean: 1.08; 95% CI: 0.25, 1.91; P = 0.011) and 2 tests of visual-motor coordination (mean: -2.95; 95% CI: -5.33, -0.57; P = 0.015 and mean: -9.44; 95% CI: -18.60, -0.30; P = 0.043, respectively). The better scores for EPA and DHA were due to an improvement at 12 mo compared with baseline in verbal fluency, language, and memory (P = 0.047) and 2 tests of visual-motor coordination (P = 0.033 and P < 0.001, respectively), whereas control had no change. Post hoc analyses indicated no difference by age, sex, or diabetes status. CONCLUSIONS: Cognitively healthy older adults with stable CAD randomly assigned to high-dose EPA and DHA had improved cognitive function over a 30-mo period compared with control. These findings may be especially important for CAD patients because CAD is a risk factor for cognitive decline.This trial was registered at clinicaltrials.gov as NCT01624727.
BACKGROUND: Omega-3 (n-3) fatty acids have shown benefit in cognitively impaired subjects, but the effect on cognitively healthy older subjects is unclear. OBJECTIVES: Our aim was to determine if long-term, high-dose ω-3 ethyl esters, EPA (20:5n-3) and DHA (22:6n-3), prevent deterioration of cognitive function in cognitively healthy older adults. METHODS: A total of 285 subjects with stable coronary artery disease (CAD) on statin treatment were randomly assigned to 3.36 g EPA and DHA or none (control) for 30 mo. Cognitive function was assessed in all 285 subjects at baseline and in 268 and 250 subjects who returned at 12- and 30-mo follow-up, respectively, with neuropsychological testing as a prespecified secondary outcome. A completer's analysis, along with a sensitivity analysis carrying forward the last observation, was performed. RESULTS: Over the 30-mo period, subjects randomly assigned to EPA and DHA had significantly better scores than control for verbal fluency, language, and memory (mean: 1.08; 95% CI: 0.25, 1.91; P = 0.011) and 2 tests of visual-motor coordination (mean: -2.95; 95% CI: -5.33, -0.57; P = 0.015 and mean: -9.44; 95% CI: -18.60, -0.30; P = 0.043, respectively). The better scores for EPA and DHA were due to an improvement at 12 mo compared with baseline in verbal fluency, language, and memory (P = 0.047) and 2 tests of visual-motor coordination (P = 0.033 and P < 0.001, respectively), whereas control had no change. Post hoc analyses indicated no difference by age, sex, or diabetes status. CONCLUSIONS: Cognitively healthy older adults with stable CAD randomly assigned to high-dose EPA and DHA had improved cognitive function over a 30-mo period compared with control. These findings may be especially important for CAD patients because CAD is a risk factor for cognitive decline.This trial was registered at clinicaltrials.gov as NCT01624727.
Authors: Ling Zheng; Wendy J Mack; Helena C Chui; Lara Heflin; Dan Mungas; Bruce Reed; Charles DeCarli; Michael W Weiner; Joel H Kramer Journal: J Am Geriatr Soc Date: 2012-01-27 Impact factor: 5.562
Authors: Alan D Dangour; Elizabeth Allen; Diana Elbourne; Nicky Fasey; Astrid E Fletcher; Pollyanna Hardy; Graham E Holder; Rosemary Knight; Louise Letley; Marcus Richards; Ricardo Uauy Journal: Am J Clin Nutr Date: 2010-04-21 Impact factor: 7.045
Authors: Brian Hallahan; Timothy Ryan; Joseph R Hibbeln; Ivan T Murray; Shauna Glynn; Christopher E Ramsden; John Paul SanGiovanni; John M Davis Journal: Br J Psychiatry Date: 2016-04-21 Impact factor: 10.671
Authors: O van de Rest; J M Geleijnse; F J Kok; W A van Staveren; C Dullemeijer; M G M Olderikkert; A T F Beekman; C P G M de Groot Journal: Neurology Date: 2008-08-05 Impact factor: 9.910
Authors: Graham Mazereeuw; Nathan Herrmann; Paul I Oh; David W L Ma; Cheng Tao Wang; Alexander Kiss; Krista L Lanctôt Journal: J Clin Psychopharmacol Date: 2016-10 Impact factor: 3.153
Authors: Abdulhamied Alfaddagh; Tarec K Elajami; Hasan Ashfaque; Mohamad Saleh; Bruce R Bistrian; Francine K Welty Journal: J Am Heart Assoc Date: 2017-12-15 Impact factor: 5.501
Authors: Kay Deckers; Syenna H J Schievink; Maria M F Rodriquez; Robert J van Oostenbrugge; Martin P J van Boxtel; Frans R J Verhey; Sebastian Köhler Journal: PLoS One Date: 2017-09-08 Impact factor: 3.240